Treatment with tirzepatide in adults with pre-diabetes and obesity …
3 days ago · Zepbound ® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. INDICATION AND SAFETY SUMMARY WITH WARNINGS. Mounjaro® (mown-JAHR-OH) is an injectable medicine for adults with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose).
Lilly reports Q3 2024 financial results highlighted by strong …
INDIANAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding divestiture activity in the same period last year," said David A. Ricks, Lilly chair and CEO ...
Lilly.com | Eli Lilly and Company
INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Lilly announces new $4.5 billion site - the Lilly Medicine Foundry
INDIANAPOLIS, Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.
Lilly.com | Eli Lilly and Company
Sep 12, 2024 · INDIANAPOLIS , June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI 's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
All News - Eli Lilly and Company
Lilly's latest press releases, stories, news resources and more.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
Aug 8 (Reuters) - Eli Lilly (LLY.N) on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares...
Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in …
2 days ago · Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and obese or overweight people over 176 weeks; shares rose modestly after ...
Eli Lilly, J&J Sue US Over Rejected Changes To Drug
16 hours ago · Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.
News Release - Eli Lilly and Company
Jul 8, 2024 · Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients.